-
Nat Metab: Unhealthy lifestyles are becoming the "pusher" of cancer!
Time of Update: 2020-10-04
https://doi.org/10.1038/s42255-020-00277-4 From a comprehensive physiological point of view, such as the estype of chronic positive energy balance (That is, obesity esograms) are associated with abnormal mobilization, collection, retention, and function of specific cell types, as well as with many molecules that regulate collective disorders in the network, including metabolism, hormone regulation, immune and oxidation balance of host and tissue or tumor micro-environments, and cell and molecular levels.
-
Clin Cancer Res: The efficacy of Pabosili's combined quercitojudan anti-treatment for HER2 plus advanced breast cancer.
Time of Update: 2020-10-04
the study was a forward-looking, open-label, multi-center Phase II trial that recruited patients with advanced breast cancer who had previously received 2-4 lines of anti-HER2-based treatment.
-
Nature: A genetic map of cancer immune escape.
Time of Update: 2020-10-04
Using CRISPR screening, the team screened six mouse tumor cells for breast, colorectal, kidney and melanoma and successfully identified 182 "core cancer inherent immune escape genes" that make cancer cells more sensitive or resistant to T-cell attacks.
-
MEN1611 Dose Increase Trial for Breast Cancer Treatment: The results were encouraging.
Time of Update: 2020-10-04
the main purpose of this study was to determine the safety of MEN1611 and the dose of Phase II clinical trials (RP2D) when used in concerto-bead monoantigens/-fluoravis groups.
men1611 combination therapy has significant anti-tumor activity in patients with advanced or metastasis breast cancer.
-
Nat Commun: Phosphate status: RNF43's anti-cancer switch.
Time of Update: 2020-10-04
Multiple signal path paths that regulate the fate of cells are essential for the normal development of individuals and their own steady state.
further studies of the anti-cancer effects of the simulated phosphate recovery mutation RNF43 show that in colon cancer, simultaneous mutations of RNF43 and KRAS can promote multi-step tumor occurrence by mediating the Wnt-Ras-p53 path.
-
Nat Commun: Anti-GARP: TGF-beta 1 monoant energy overcomes PD-1/PD-L1 inhibitor resistance.
Time of Update: 2020-10-04
combined blocking garP: TGF-beta 1 and PD-1 have anti-tumor effects The study found that Treg, which expresses anti-GARP:TGF-beta-1 complex antibodies, selectively blocks the production of TGF-beta1 and inhibits the growth of tumors with PD-1 immunotherapy resistance.
-
Cell: Car-T therapy is highly neurotoxic? The latest Cell reveals key breakthroughs!
Time of Update: 2020-10-04
in a new study published September 21 in Cell, researchers from Stanford University School of Medicine and the Perelman School of Medicine at the University of Pennsylvania found expressions of CD19 in brain cells that protect the blood-brain barrier, which may be the cause of neurotoxicity in patients receiving CD19 targeted immunotherapy.
-
Br J Cancer: Next-generation antibody-drug coupled is expected to treat KRAS mutant pancreatic cancer.
Time of Update: 2020-10-04
synthesis of antibody-drug coupleds the study produced a highly refined ADC of anti-EGFR (the skin growth factor complex) by reconnectoring cetuximab (CTX) interchains of disulides with aristatin.
-
Br J Cancer: Natural 芫 cholesterol synthesis inhibits the development of liver cancer.
Time of Update: 2020-10-04
the expression and activity of DHCR24, cholesterol levels, lipid raft structure, and the role of DHCR24 in human liver cancer samples through relevant molecular biology experiments.
The biosynthetic process of DHCR24-mediated cholesterol and the formation of lipid rafts ultimately inhibit the invasion and migration of HCC cells.
-
Gilead and Mercedon are both in the business, and the ADC field is expected to have more than $1 billion in new drugs in four years' time.
Time of Update: 2020-10-04
In recent days, two drug companies have completed two heavyweight deals involving (antibody-coupled) ADC drugs , one in Gilead's $21 billion acquisition of oncology-focused Immunomedics and the other in a $4.5 billion strategic partnership with Seattle Genetics.
-
Stem Cell Reports: Men are more likely to develop colorectal cancer, which is associated with androgen levels.
Time of Update: 2020-10-03
overall, the study sheds light on the role of male hormones in promoting proliferation and inhibiting differentiation, suggesting that substrate cells form the microenvironment of intestinal stem cells and providing a possible explanation for the high incidence of colorectal cancer in men.
-
Keystone Pharmaceuticals Shugli single anti-first-line data debuted in ESMO, stomach cancer, esophageal squamous cancer to welcome a new breakthrough.
Time of Update: 2020-10-03
01 Study Design GC/GEJ(1L) queue: Includes locally advanced or metastatic gastric or gastroesophageal combined cancer patients who have not been systematically treated in the past and cannot be surgically removed.
-
Br J Cancer: Effect of ER expression status on the prognosmation of BRCA2 mutant breast cancer.
Time of Update: 2020-10-03
survival analysis of 584 patients showed that ER-positive was a protective factor in the first 5 years of diagnosis (risk ratio of HR s 0.49), followed by adverse effects (HR s 1.91).
-
JAMA Surg: Effects of double mastectomy on the quality of life and psychosociality of young breast cancer patients.
Time of Update: 2020-10-03
of the study were patients' physical function, body image, sexual health, anxiety, and depressive symptoms, assessed on an adjusted average score, and higher scores indicated poor function.
-
Br J Cancer: New urine protein markers may be used in early gastric cancer diagnosis.
Time of Update: 2020-10-03
study flowchart researchers found that, in addition to Helicobacter proteomic analysis of related urine proteins, the expression levels of TFF1 (uTFF1) and ADAM12 (uADAM12) in urine were key indicators of GC diagnosis.
in the training and validation queues, groups using uTFF1, uADAM12, and Helicobacter pyridosis can distinguish HC and GC patients significantly.
-
The departure of Vice President Gilead Kite, the extension of bayer's CEO tenure, the addition of the head of BMS oncology research and development to Blueprint...
Time of Update: 2020-10-03
Peter Emage's role will now be temporarily taken over by Ken Takeshita, Senior Vice President and Global Head of Clinical Development at Kite, and the company will continue to seek a new successor, according to people familiar with the matter.
-
Cancer Res: A double-edged sword in the human body! This substance is too high to increase the risk of cancer!
Time of Update: 2020-10-03
A recent study of nearly 400,000 participants and 30 cancers found a significant positive correlation between elevated levels of IGF-1 and increased risk of thyroid, multiple myeloma and malignant melanoma, as well as further evidence of its link to breast, prostate and colorectal cancers.
-
Nature Metabolism: Unhealthy lifestyles are becoming the "pushers" of cancer!
Time of Update: 2020-10-03
From a comprehensive physiological point of view, esograms such as chronic positive energy balance (i.e., obesity espresso) are associated with abnormal mobilization, collection, retention, and function of specific cell types, as well as with molecules that regulate collective disorders in networks, including metabolism, hormone regulation, immune and oxidation balance of host and tissue or tumor micro-environments, and cell and molecular levels.
-
Nature Immunology: Proactively, cancer cells induce immune cells to store lipids in advance to help them metastasy their lungs.
Time of Update: 2020-10-03
study, the authors used a mouse breast cancer model to find that from the pre-transfer stage, the bone marrow-sourced neutral granulocytes accumulated a large amount of lipids after being immersed in the lungs.
-
Treatment of soft tissue sarcoma! Regency BioPD-1 has been recognized as the FDA's third orphan drug.
Time of Update: 2020-10-03
May 2020, a new adaptation application for Therepri monoantigen injections used to treat local progressions or metastatic urethra cancers that have been systematically treated in the past was accepted by the National Drug Administration.
